By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sangart, Inc. 

11189 Sorrento Valley Road, Suite 104

San Diego  California    U.S.A.
Phone: 858-455-0966 Fax: 858-455-6963


Company News
Sangart, Inc. Completes Patient Enrollment in Phase 2B Clinical Trial of MP4OX in Traumatic Hemorrhagic Shock Patients 10/9/2012 7:36:06 AM
Sangart, Inc. Grabs $50 Million Series G Funding 5/25/2012 6:42:13 AM
Sangart, Inc. Enhances Leadership Team Bringing Superior Depth of Expertise 2/15/2012 9:26:26 AM
Sangart, Inc. Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease 1/13/2012 10:04:35 AM
Sangart, Inc. Plans Extra Hiring at Irish Plant 8/23/2011 7:20:20 AM
Pharma Firm Sangart, Inc. to Create 245 Jobs in Ireland 7/21/2011 8:14:43 AM
Sangart, Inc. Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 6/14/2011 8:51:14 AM
Sangart, Inc. Announces Closing of $50 Million Series G Financing 4/20/2011 7:04:08 AM
Sangart, Inc. Announces Cooperative Research and Development Agreement With the U.S. Navy to Evaluate MP4 Molecule in Traumatic Brain Injury 12/6/2010 8:58:17 AM
Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease 11/15/2010 10:18:15 AM